MedPath, LLC – Trademark Portfolio

Entity Type: 16

MedPath, LLC holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 45 (Legal & Security Services) — 2 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 1 trademark is registered and 2 are pending. Notable registered marks include MEDPATH. The owner is based in Las Vegas, NV.

1108 Golden Age Court

Las Vegas, NV 89144

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

MPATH
MPATH
Pending 2025
MEDPATH
MEDPATH
Pending 2024
MEDPATH
MEDPATH
Registered 2024

Trademark Classifications

MedPath, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

45
Legal & Security Services (2 filings)

Legal services; security services for the protection of property and individuals

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does MedPath, LLC have?

MedPath, LLC has 3 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 pending.

What trademark classes does MedPath, LLC file in?

MedPath, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 45 (Legal & Security Services), Class 42 (Computer & Scientific). Class 45 covers legal services; security services for the protection of property and individuals.

What are MedPath, LLC's most well-known trademarks?

MedPath, LLC's registered trademark portfolio includes well-known marks such as MEDPATH. These are among 1 currently registered trademark in the portfolio.

What is MedPath, LLC's trademark registration success rate?

MedPath, LLC has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 2 applications are pending review.